Related Experiment Videos
Mammalian target of rapamycin
Funda Meric-Bernstam1, Gordon B Mills
1University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Seminars in Oncology
|April 1, 2005
Summary
Targeted molecular therapies offer a promising, non-toxic approach to cancer treatment by targeting specific genetic abnormalities. Linking molecular diagnostics with these advanced therapeutics is crucial for effective individualized cancer care.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted molecular therapeutics exploit genetic abnormalities driving cancer progression.
- Modulating aberrant signaling pathways in cancer cells presents a potential non-toxic therapy.
- Several targeted agents have shown remarkable responses in specific patient subsets.
Purpose of the Study:
- To review novel molecules targeting the phosphatidylinositol 3-kinase (PI3K) pathway.
- To illustrate challenges in implementing molecular therapeutics for breast and ovarian cancers.
- To emphasize the need for identifying specific aberrant pathway components for individualized therapy.
Main Methods:
- Review of existing literature on targeted molecular therapeutics.
- Focus on agents targeting BCR-ABL, retinoid receptors, HER2/neu, EGFR, and the PI3K pathway.
- Discussion of molecular diagnostics, intermediary markers, and molecular imaging.
Main Results:
- Targeted agents like imatinib, trastuzumab, and others have demonstrated efficacy in specific cancers.
- Molecular diagnostics are essential for identifying patients with aberrant targets.
- Intermediary markers and imaging are needed to determine biologically relevant drug doses.
Conclusions:
- Successful individualized cancer therapy requires identifying specific aberrant signaling pathway drivers.
- Integrating molecular diagnostics with molecular therapeutics is key to improving patient outcomes.
- The PI3K pathway and its targeted agents are a focus for advancing breast and ovarian cancer treatment.